Ratings Sectra AB

Equities

SECT B

SE0020539310

Market Closed - Nasdaq Stockholm Other stock markets 11:29:38 2024-04-26 EDT			5-day change	1st Jan Change
221.6 ^SEK	+2.12%		+6.64%	+22.93%

04-23	University Medical Centers in Germany Selects Sectra AB's Radiology Solution to Streamline Workflows and Longer Lead Times for Patients	CI
03-14	Halton Healthcare Selects Sectra's Cloud SaaS to Optimize Enterprise Imaging Workflows and Strengthen Security	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 65% by 2026.
The company returns high margins, thereby supporting business profitability.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Over the past four months, analysts' average price target has been revised upwards significantly.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

With an expected P/E ratio at 104.78 and 86.9 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SECTRA AB	+22.93%	3.89B		B-
VEEVA SYSTEMS INC.	+4.36%	32.47B		C
PRO MEDICUS LIMITED	+14.14%	7.45B		C-
EVOLENT HEALTH, INC.	-16.29%	3.17B		C-
OMNICELL, INC.	-25.96%	1.28B		B
LUNIT INC.	-36.14%	1.09B		-
B-SOFT CO.,LTD.	-35.42%	902M		-
SIMULATIONS PLUS, INC.	-0.13%	893M		C
VERADIGM INC.	-24.12%	857M	-	C+
SURGICAL SCIENCE SWEDEN AB	-18.47%	693M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes